Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
LAURION Retains SMARTIR Marketing Ltd. to Drive Investor Awareness Ahead of Active 2026 Exploration Program
LaFleur Minerals Engages Leading Executive Search Firm to Recruit Senior Mining Executive as Company Advances Toward Gold Production
SAGA Metals Closes on Title Transfer Agreement to Expand Wolverine Heavy Rare Earth Element Project in Labrador-Grab Sample Assays Included up to 21.6% TREO
